Skip to main content

Advertisement

SpringerLink
Log in

Optimizing blood pressure control in the obese patient

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Obesity is a major public health issue, and hypertension is one of the most common associated comorbidities. Current guidelines for optimal blood pressure levels in obese patients or for the treatment of obesity-hypertension do not provide specific recommendations that go beyond the rather general recommendation to lose weight. Based on the strong ties between obesity, hypertension, and type 2 diabetes, and the similarity of complications that occur in obesity-related hypertension and in hypertension associated with type 2 diabetes, it seems appropriate to explore the optimal blood pressure levels for obese hypertensive patients. Recently published studies underline the importance of weight reduction to reach this goal. Several lines of reasoning support the use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers as the appropriate first-line therapy in obese patients with uncomplicated hypertension. Nondihydropyridine calcium channel blockers, α-blockers, or low-dose diuretics may be added when necessary. Clearly, further studies are needed to define target blood pressure levels in obese patients and to clarify the value of established and newer drugs, like angiotensin receptor blockers, for the treatment of obese hypertensive patients. The role of antiobesity drugs in the management of the obese hypertensive patient also remains to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Seidell JC: Obesity, insulin resistance and diabetes-- a worldwide epidemic. Br J Nutr 2000, 83(Suppl 1):S5–8.

    PubMed  CAS  Google Scholar 

  2. Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529.

    Article  PubMed  CAS  Google Scholar 

  3. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413–2446.

  4. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999, 17:151–183.

  5. Groop L, Orho-Melander M: The dysmetabolic syndrome. J Intern Med 2001, 250:105–120.

    Article  PubMed  CAS  Google Scholar 

  6. Rewers M, Hamman RF: Risk factors for non-insulindependent diabetes. In Diabetes in America [NIH Publication No. 95-1468]. Edited by National Diabetes Data Group. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:179–220.

    Google Scholar 

  7. Hu FB, Manson JE, Stampfer MJ, et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790–797.

    Article  PubMed  CAS  Google Scholar 

  8. Cowie CC, Harris MI: Physical and metabolic characteristics of persons with diabetes. In Diabetes in America [NIH Publication No. 95-1468]. Edited by National Diabetes Data Group. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:117–164.

    Google Scholar 

  9. Ferrannini E, Natali A, Capaldo B, et al.: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997, 30:1144–1149.

    PubMed  CAS  Google Scholar 

  10. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713–720. This study documents the importance of tight blood pressure control in type 2 diabetics.

    Google Scholar 

  11. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762. This study demonstrates the benefits and safety of intensive antihypertensive treatment.

    Article  PubMed  CAS  Google Scholar 

  12. American Diabetes Association: Diabetic nephropathy. Diabetes Care 2002, 25(Suppl 1):S85-S89.

    Google Scholar 

  13. Liese AD, Hense HW, Doring A, et al.: Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001, 15:799–804.

    Article  PubMed  CAS  Google Scholar 

  14. Mulyadi L, Stevens C, Munro S, et al.: Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001, 45:67–71.

    Article  PubMed  CAS  Google Scholar 

  15. Valensi P, Assayag M, Busby M, et al.: Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996, 20:574–579.

    PubMed  CAS  Google Scholar 

  16. Sasatomi Y, Tada M, Uesugi N, et al.: Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology 2001, 69:113–118.

    Article  PubMed  CAS  Google Scholar 

  17. Hall JE, Brands MW, Henegar JR, Shek EW: Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998, 25:58–64.

    PubMed  CAS  Google Scholar 

  18. Messerli FH, Sundgaard-Riise K, Reisin ED, et al.: Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983, 99:757–761.

    PubMed  CAS  Google Scholar 

  19. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134–147.

    Article  PubMed  Google Scholar 

  20. Eckel RH: Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997, 96:3248–3250.

    PubMed  CAS  Google Scholar 

  21. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968–977.

    PubMed  CAS  Google Scholar 

  22. Kriketos AD, Robertson RM, Sharp TA, et al.: Role of weight loss and polyunsaturated fatty acids in improving metabolic fitness in moderately obese, moderately hypertensive subjects. J Hypertens 2001, 19:1745–1754.

    Article  PubMed  CAS  Google Scholar 

  23. Saltzman E, Das SK, Lichtenstein AH, et al.: An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. J Nutr 2001, 131:1465–1470.

    PubMed  CAS  Google Scholar 

  24. Ard JD, Rosati R, Oddone EZ: Culturally-sensitive weight loss program produces significant reduction in weight, blood pressure, and cholesterol in eight weeks. J Natl Med Assoc 2000, 92:515–523.

    PubMed  CAS  Google Scholar 

  25. Metz JA, Stern JS, Kris-Etherton P, et al.: A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160:2150–2158.

    Article  PubMed  CAS  Google Scholar 

  26. Blumenthal JA, Sherwood A, Gullette EC, et al.: Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000, 160:1947–1958. This study documents the importance of physical activity as an adjunct to weight loss in blood pressure control.

    Article  PubMed  CAS  Google Scholar 

  27. Sharma AM: Effects of nonpharmacological intervention on insulin sensitivity. J Cardiovasc Pharmacol 1992, 20:S27-S34.

    PubMed  Google Scholar 

  28. Kolanowski J: Obesity and hypertension: from pathophysiology to treatment. Int J Obes Relat Metab Disord 1999, 23(Suppl 1):42–46.

    Article  PubMed  Google Scholar 

  29. Langford HG, Davis BR, Blaufox D, et al.: Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension 1991, 17:210–217.

    PubMed  CAS  Google Scholar 

  30. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N Engl J Med 2001, 344:3–10.

    Article  PubMed  CAS  Google Scholar 

  31. Guerciolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 1997, 21(Suppl 3):S12-S23.

    PubMed  CAS  Google Scholar 

  32. Sjostrom L, Rissanen A, Andersen T, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167–172. First 2-year study documenting the sustained weight lowering effect of combining orlistat with a weight maintenace progam.

    Article  PubMed  CAS  Google Scholar 

  33. Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242. This study demonstrated that 2-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.

    Article  PubMed  CAS  Google Scholar 

  34. Hauptman J, Lucas C, Boldrin MN, et al.: Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160–167. This study demonstrates that the beneficial effects of pharmacologically induced weight loss can be achieved in general practice.

    Article  PubMed  CAS  Google Scholar 

  35. Rossner S, Sjostrom L, Noack R, et al.: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000, 8:49–61.

    PubMed  CAS  Google Scholar 

  36. Finer N, James WP, Kopelman PG, et al.: One-year treatment of obesity: a randomized, double-blind, placebo- controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000, 24:306–313.

    Article  PubMed  CAS  Google Scholar 

  37. Hazenberg BP: Randomized, double-blind, placebocontrolled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000, 94:152–158. This study documents the weight lowering effect of sibutramine in obese hypertensive patients.

    Article  PubMed  CAS  Google Scholar 

  38. McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000, 160:2185–2191. This study showed that in obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance.

    Article  PubMed  CAS  Google Scholar 

  39. Scholze J: Sibutramine in clinical practice — a PMS-study with positive effects on blood pressure and metabolic parameters. Deutsch Med Wochenschr 2002, 127:606–610.

    Article  CAS  Google Scholar 

  40. Expert Panel: Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.

    Article  Google Scholar 

  41. Haciyanli M, Erkan N, Bora S, Gulay H: Vertical banded gastroplasty in the Aegean region of Turkey. Obes Surg 2001, 11:482–486.

    Article  PubMed  CAS  Google Scholar 

  42. Giese SY, Bulan EJ, Commons GW, et al.: Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study. Plast Reconstr Surg 2001, 108:510–521.

    Article  PubMed  CAS  Google Scholar 

  43. Thorne A, Lonnqvist F, Apelman J, et al.: A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002, 26:193–199.

    Article  PubMed  CAS  Google Scholar 

  44. Torgerson JS, Sjostrom L: The Swedish Obese Subjects (SOS) study--rationale and results. Int J Obes Relat Metab Disord 2001, 25(Suppl 1):S2-S4. This is the largest ongoing study on obesity surgery and its effect on obesity-related comorbities. It demonstrates that in contrast to diabetes, long-term development of hypertension is not prevented by surgically induced weight loss.

    Article  PubMed  Google Scholar 

  45. Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667–674. This paper comments on the lack of guidelines and paucity of evidence on the pharmacologic management of the obese hypertensive patient.

    Article  PubMed  CAS  Google Scholar 

  46. Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38:705–708.

    PubMed  CAS  Google Scholar 

  47. Messerli FH, Kaesser UR, Losem CJ: Effects of antihypertensive therapy on hypertensive heart disease. Circulation 1989, 80:IV145-IV150.

    PubMed  CAS  Google Scholar 

  48. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003. This large intervention study demonstrated that losartan prevents more cardiovascular morbidity and death and lowers the incidence of type 2 diabtes compared with atenolol for a similar reduction in blood pressure.

    Article  PubMed  CAS  Google Scholar 

  49. Garg R, Yusuf S: Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  50. Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  51. Kasiske BL, Kalil RS, Ma JZ, et al.: Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993, 118:129–138.

    PubMed  CAS  Google Scholar 

  52. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  53. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912. This study demonstrated that subjects with hypertension who were taking ß-blockers had a 28% higher risk of subsequent diabetes.

    Article  PubMed  CAS  Google Scholar 

  54. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868–873.

    Article  PubMed  CAS  Google Scholar 

  55. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. This intervention trial showed that ramipril significantly reduces the rates of death, myocardial infarction, and stroke and reduces the incidence of type 2 diabetes in a broad range of high-risk patients.

    Article  PubMed  CAS  Google Scholar 

  56. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  57. Schmieder RE, Gatzka C, Schachinger H, et al.: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537–540.

    Article  PubMed  CAS  Google Scholar 

  58. Stoa-Birketvedt G, Thom E, Aarbakke J, Florholmen J: Body fat as a predictor of the antihypertensive effect of nifedipine. J Intern Med 1995, 237:169–173.

    Article  PubMed  CAS  Google Scholar 

  59. Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992, 19:156–160.

    Google Scholar 

  60. Tuck ML: Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992, 19:167–177.

    Google Scholar 

  61. Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8:461–466.

    Article  PubMed  CAS  Google Scholar 

  62. Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140–145.

    PubMed  CAS  Google Scholar 

  63. Stein PP, Black HR: Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991, 14:425–448.

    Article  PubMed  CAS  Google Scholar 

  64. Lehtonen A: Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J 1991, 121:1307–1311.

    Article  PubMed  CAS  Google Scholar 

  65. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420.

    Article  PubMed  CAS  Google Scholar 

  66. Grassi G, Cattaneo BM, Seravalle G, et al.: Obesity and the sympathetic nervous system. Blood Press Suppl 1996, 1:43–46.

    PubMed  CAS  Google Scholar 

  67. CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.

    Article  Google Scholar 

  68. Koch R, Sharma AM: Obesity and cardiovascular hemodynamic function. Curr Hypertens Rep 1999, 1:127–130.

    Article  PubMed  CAS  Google Scholar 

  69. Messerli FH, Nunez BD, Ventura HO, Snyder DW: Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987, 147:1725–1728.

    Article  PubMed  CAS  Google Scholar 

  70. Jouven X, Desnos M, Guerot C, Ducimetiere P: Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999, 99:1978–1783.

    PubMed  CAS  Google Scholar 

  71. Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: Betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250–254. This paper extensively reviews the relationship between weight gain and ß-adrenergic blockade.

    PubMed  CAS  Google Scholar 

  72. Gambardella S, Frontoni S, Pellegrinotti M, et al.: Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol 1993, 22:S87-S97.

    PubMed  Google Scholar 

  73. Morel Y, Gadient A, Keller U, et al.: Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995, 26:306–311.

    Article  PubMed  CAS  Google Scholar 

  74. MacMahon SW, Macdonald GJ, Bernstein L, et al.: Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985, 1:1233–1236.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Franz Volhard Clinic - Charit’e, Wiltbergstrasse 50, 13125, Berlin, Germany

    Tobias Pischon MD, MPH & Arya M. Sharma MD

Authors
  1. Tobias Pischon MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arya M. Sharma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pischon, T., Sharma, A.M. Optimizing blood pressure control in the obese patient. Current Science Inc 4, 358–362 (2002). https://doi.org/10.1007/s11906-002-0064-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-002-0064-8

Keywords

Search

Navigation